This month, Genesis Capital, together with Washington H Soul Pattinson (SOL), made a takeover offer for Monash IVF – The offer was for 80c per share, valuing the company at roughly $312 million. The stock is trading above the bid, suggesting there’s more water to go under the bridge here. The board of Monash IVF rejected this initial salvo, describing it as “opportunistic, unsolicited, conditional and …. materially undervaluing” the company. Despite the rejection, the consortium now holds ~19.6% of MVF — making them the company’s largest shareholder.
- We can see a revised bid for MVF around the 95c region, which could get shareholder approval following the tough 18 months.
MM is neutral towards MVF around 90c
Add To Hit List
The four stocks which are in play have performed very differently through 2024/25, but the three we have looked at below have all struggled, suggesting any suitor bid would be looking for deep-seated value. Two of these we have considered before, and they’ve now gotten cheaper!
